➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
McKinsey
Medtronic
Mallinckrodt
Baxter

Last Updated: June 5, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for CC-220


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug CC-220?

CC-220 is an investigational drug.

There have been 11 clinical trials for CC-220. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2014.

The most common disease conditions in clinical trials are Multiple Myeloma, Lupus Erythematosus, Systemic, and Neoplasms, Plasma Cell. The leading clinical trial sponsors are Celgene Corporation, Celgene, and VU University Medical Center.

There are twenty US patents protecting this investigational drug and two hundred and twelve international patents.

Recent Clinical Trials for CC-220
TitleSponsorPhase
Iberdomide Combined With Low-dose Cyclophosphamide and DexamethasoneCelgenePhase 2
Iberdomide Combined With Low-dose Cyclophosphamide and DexamethasoneVU University Medical CenterPhase 2
Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy SubjectsCelgenePhase 1

See all CC-220 clinical trials

Clinical Trial Summary for CC-220

Top disease conditions for CC-220
Top clinical trial sponsors for CC-220

See all CC-220 clinical trials

US Patents for CC-220

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CC-220   Start Trial Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies Celgene Corporation (Summit, NJ)   Start Trial
CC-220   Start Trial Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin- e-2,6-dione Celgene Corporation (Summit, NJ)   Start Trial
CC-220   Start Trial Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast Celgene Corporation (Summit, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
AstraZeneca
Medtronic
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.